Natera, Inc. (NASDAQ:NTRA) Insider Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the firm’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total value of $421,440.00. Following the completion of the transaction, the insider now directly owns 141,782 shares of the company’s stock, valued at approximately $19,917,535.36. This trade represents a 2.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The shares were sold at an average price of $146.04, for a total transaction of $149,837.04.
• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The shares were sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.

Natera Stock Down 3.1 %

Natera stock traded down $4.49 during midday trading on Thursday, reaching $138.71. The stock had a trading volume of 1,459,315 shares, compared to its average volume of 1,373,443. The stock has a market capitalization of $18.75 billion, a P/E ratio of -78.81 and a beta of 1.80. The firm’s fifty day simple moving average is $157.48 and its 200-day simple moving average is $151.20. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. The Manufacturers Life Insurance Company grew its holdings in shares of Natera by 87.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock valued at $8,621,000 after acquiring an additional 31,649 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Natera by 5.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company’s stock valued at $3,344,000 after purchasing an additional 1,263 shares during the last quarter. Captrust Financial Advisors grew its stake in Natera by 108.7% in the third quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company’s stock valued at $722,000 after purchasing an additional 2,963 shares in the last quarter. Paloma Partners Management Co bought a new position in Natera in the third quarter valued at approximately $238,000. Finally, Benjamin Edwards Inc. increased its position in shares of Natera by 15,167.3% during the 3rd quarter. Benjamin Edwards Inc. now owns 7,481 shares of the medical research company’s stock worth $950,000 after purchasing an additional 7,432 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent research reports. Piper Sandler increased their price objective on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Barclays started coverage on Natera in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target for the company. Robert W. Baird increased their price target on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Canaccord Genuity Group restated a “buy” rating and set a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. Finally, Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 target price on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.